ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 1082

Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0850

Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0662

Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0648

Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0742

Patient Factors Influencing Recruitment in a Telemedicine Randomized Clinical Trial

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0610

Patient-derived Organoids Reveal Transcriptional Regulation of Synovial Lining Fibroblast Differentiation

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0906

Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0967

Patterns of Breastfeeding Among Women with and Without Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0911

Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0631

Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0803

Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 1037

Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies

Spondyloarthritis Including PsA – Treatment Poster II: Mixed

9:00AM-10:30AM: Abstract Number: 1080

Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0899

Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0612

Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response

RA – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].